Although schizophrenia clinical trials returned negative results with previous molecules, such as JNJ-40411813 or AZD8529, further preclinical and clinical studies may contribute to defining the potential of these and other improved mGluR2 PAMs as novel therapeutic agents, as well as their optimal therapeutic uses [32]. Here, GRM2 is linked to schizophrenia.